FDA questions Lilly, Amgen cancer drug trials

By Susan Heavey

WASHINGTON (Reuters) - U.S. health regulators are questioning whether clinical trials proposed by ImClone Systems and Amgen Inc will be adequate to show that patients with a certain type of gene are more likely to be helped by two cancer drugs, according to documents released on Friday.

Early research has indicated that patients with the normal, so-called “wild type” of a gene known as K-ras respond far better to treatment with ImClone’s Erbitux and Amgen’s Vectibix than those with a mutated form of the gene.

On Tuesday, the U.S. Food and Drug Administration will seek advice from outside experts on what type of clinical trial the companies need to conduct to confirm the findings.

While eliminating patients with a mutated K-ras gene from treatment would cut sales of the drugs, the findings could be a significant advance toward so-called specialized medicine in which genetic testing can determine who is most likely to benefit from expensive drugs.

ImClone, recently acquired by Eli Lilly and Co. and Bristol-Myers Squibb Co, co-market Erbitux in the United States.

Both ImClone and Amgen have proposed retrospective testing of K-ras status from large randomized trials that have already been designed and have recruited patients or are still looking to enroll them, the FDA said in documents released ahead of Tuesday’s meeting.

The drugmakers modified the ongoing studies to enroll only patients with the wild type K-ras gene, the FDA said.

Amgen has already enrolled patients in two, large ongoing studies but made changes before conducting any K-ras testing, the company said in a separate document. Results are expected next year.

Enrollment in two earlier trials for ImClone’s Erbitux were halted after the K-ras finding so patients could be informed. Patients are still being sought for another ongoing trial that was put on hold, the company said.

“It is no longer feasible to conduct clinical trials in patients with MT (mutant) K-ras in their tumors,” it wrote.

Amgen shares were up 0.6 percent at $57.59 on Nasdaq. Lilly shares were also up 0.6 percent, at $35.84, and Bristol was up 3.5 percent at $22.21 on the New York Stock Exchange.

The documents were posted on the agency’s Website here

(Editing by Gerald E. McCormick, Dave Zimmerman)


Related Posts:

LONDON (Reuters) - Scientists have uncovered a second gene mutation that determines which patients will respond to the bowel cancer drugs Erbitux and Vectibix, opening the way to still more targeted treatment. Treating patients based on their genetic make-up is a growing trend in oncology, and the latest research, reported at a medical meeting in Geneva

Full Post: New gene mutation linked to cancer drugs’ success

FRANKFURT (Reuters) - Merck KGaA said on Wednesday a Phase II trial provided further evidence that its cancer drug Erbitux was particularly effective at fighting bowel tumors whose cells did not undergo a certain type of genetic mutation. The German drugs and chemicals maker said that 53 percent of patients who did not have a mutation

Full Post: Merck says study confirms efficacy of Erbitux drug

By Deena Beasley LOS ANGELES (Reuters) - Patients treated with GlaxoSmithKline PLC’s Promacta rather than a placebo were eight times more likely to have sustained increases in platelet counts, according to pivotal trial results announced by the company on Saturday. Promacta, also known as eltrombopag, was approved by the U.S. Food and Drug Administration last month for

Full Post: Glaxo says oral drug raises blood platelet counts

By Maggie Fox, Health and Science Editor WASHINGTON (Reuters) - Combining two chemotherapy drugs with two targeted therapies was safe and appeared to help patients with advanced lung cancer live longer, U.S. researchers reported on Thursday. The combination of Roche and Co’s Avastin, ImClone’s Erbitux, carboplatin and paclitaxel appeared to add an average of two months to

Full Post: Four drug combination helps in lung cancer: U.S. study

By Ben Hirschler LONDON (Reuters) - Nearly one in five cancer drugs entering development now reach the market, a remarkably good success rate given the high level of failures in other disease areas, British researchers said on Friday . A study by Cancer Research UK, based on 974 cancer drugs starting initial Phase I clinical trials since

Full Post: Modern cancer drugs more likely to get to market

Site Navigation

Most Read



  • kinwrite.com@gmail.com